Lipocine Inc.

Lipocine is a clinical-stage biopharmaceutical company developing oral drug candidates focused on central nervous system disorders and metabolic conditions. The company's most advanced product is TLANDO, an oral testosterone replacement therapy based on testosterone undecanoate formulation technology. Beyond testosterone replacement, Lipocine's pipeline addresses conditions including postpartum depression, cirrhosis, epilepsy in women, essential tremor, metabolic dysfunction-associated steatohepatitis, obesity, and recurrent preterm birth prevention.

The company operates as a research and development organization without disclosed revenue streams, as its candidates remain in clinical development stages. Its therapeutic approach emphasizes oral formulations and prodrug technology to improve drug delivery and patient outcomes. Lipocine was founded in 1997 and is incorporated in Delaware with headquarters in Salt Lake City, Utah.

The company operates with a lean organizational structure of approximately 16 full-time employees. As a Nasdaq-listed clinical-stage entity with a market capitalization of $0.1 billion, Lipocine operates primarily from its Salt Lake City location with focus on advancing its clinical pipeline candidates through regulatory processes.